Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

30,397292,193Patent filing fees, net

807,357701,846Other assets

59,56875,394Total assets$
8,750,079$
4,086,177LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIESAccounts payable and accrued expenses 

$
,199,662$
,843,684Accrued bonus expense

465,865582,675Other current liabilities

90,776-Total current liabilities1,756,3032,426,359Deferred rent, net of current portion

21,143-Total liabilities

1,777,4462,426,359STOCKHOLDERS' EQUITYPreferred stock, 7,000,000 shares authorized, zero shares issued and outstanding

--Common stock, $0.01 par value; 150 million shares authorized,  68,189,314 and 48,682,118 shares outstanding in 2012 and 2011,respectively

681,893486,821Additional paid-in capital

114,884,91599,645,655Accumulated deficit

(108,594,175)(98,472,658)Total stockholders' equity6,972,6331,659,818Total liabilities and stockholders' equity$
8,750,079$
4,086,177 Neuralstem, Inc.Statements of OperationsYear Ended December 31,20122011Revenues

$
407,708$
390,625Operating expenses:Research and development costs

6,105,9847,354,857General and administrative expenses

4,247,0375,839,188Depreciation and amortization

211,143187,050Total operating expenses

10,564,16413,381,095Operating loss

(10,156,456)(12,990,470)Other income (expense):Litigation settlement

3,484250,000Interest income

34,15460,955Interest expense

(2,699)(821)Gain from change in fair value of warrant obligations

-161,809Total other income (expense) 

34,939471,943Net loss

$
(10,121,517)$
(12,518,527)Net loss per share - basic and diluted

$
(0.17)$
(0.26)Weighted average common shares outstanding - basic and diluted

58,153,92948,340,557 

About Neuralstem

Neuralstem's patented technology enables the ability to produce n
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Feb. 3 .decimal, Inc. announced today that,it ... Inc. to supply,patient-specific devices for its proton therapy ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO ) , ... have a formal agreement signed with ProCure to ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in ... There was no statistical significance observed between the ... the study, peak walking time (PWT), did not ...
... Feb. 3 Cardium Therapeutics,(NYSE: CXM ) ... New,England Journal of Medicine showing the long-term outcome of ... a fatal disorder of the immune system.,The infant children ... SCID arises in infants with a genetic defect ...
Cached Biology Technology:ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5
(Date:10/16/2014)... land managers have a new synthesis of recent research ... (MMC) forests in the two states. , The ... Oregon and Washington: A Synthesis of the Relevant Biophysical ... technical report published by the U.S. Forest Service,s Pacific ... request from managers for a synthesis of the large ...
(Date:10/16/2014)... Northridge, Calif. (October 16, 2014) – Post-menopausal women ... effect on hormone levels or genital bleeding, after ... of an investigational fermented soy germ-based nutritional supplement ... according to a new peer-reviewed pilot study reported ... Society (NAMS) annual scientific meeting. , "These ...
(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2
... MIAMI African-American women with breast cancer living ... in treatment regardless of insurance type, socioeconomic status and ... A. Young, Ph.D., an associate professor of epidemiology at ... difficulties in measuring the impact of race and socioeconomic ...
... , BUFFALO, N.Y. -- Biomedical researchers at the University ... can grow continuously in culture, a discovery that could ... disease, diabetes, immune disorders and neurodegenerative diseases. , UB ... Universal" by genetically altering mesenchymal stem cells, which ...
... the past three decades, saturated fat has been considered a major ... persists in recommending reduced consumption of this macronutrient. However, new ... impact on CVD risk -- causing many to rethink the "saturated ... articles published in the October issue of Lipids ...
Cached Biology News:Racial differences in breast cancer treatment persist despite similar economics 2Researchers engineer adult stem cells that do not age 2Think saturated fat contributes to heart disease? Think again 2Think saturated fat contributes to heart disease? Think again 3
... /K + ATPase α-1, clone C464.6 ... Immunogen : Purified Na + /K + ... rabbit kidney outer medulla Formulation: 0.1M Tris-glycine, ... azide Quality Assurance: routinely evaluated in immunoblot ...
Purified anti-mouse Tim-1...
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
Biology Products: